Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Sutro Biopharma, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 130
- +13 vs. Q2 2024
- Shares held
- 62.5M
- +6.49M (+11.6%) vs. Q2 2024
- Total value
- $216.4M
- +$52.2M (+31.8%) vs. Q2 2024
- New holders
- 24
- 50 more added
- Sold out
- 11
- 31 more reduced
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 100 | $545.7M |
| Q1 2026 | 78 | $358.3M |
| Q4 2025 | 63 | $64.8M |
| Q3 2025 | 88 | $46.4M |
| Q2 2025 | 101 | $39.6M |
| Q1 2025 | 113 | $40.0M |
| Q4 2024 | 123 | $117.6M |
| Q3 2024 | 130 | $216.4M |
| Q2 2024 | 119 | $185.1M |
| Q1 2024 | 117 | $301.7M |
| Q4 2023 | 114 | $238.7M |
| Q3 2023 | 109 | $194.3M |
| Q2 2023 | 120 | $251.6M |
| Q1 2023 | 116 | $247.5M |
| Q4 2022 | 119 | $403.7M |
| Q3 2022 | 113 | $279.6M |
| Q2 2022 | 115 | $240.9M |
| Q1 2022 | 114 | $342.2M |
| Q4 2021 | 117 | $593.2M |
| Q3 2021 | 120 | $752.5M |
| Q2 2021 | 124 | $766.7M |
| Q1 2021 | 138 | $1.01B |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Sutro Biopharma, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Oconnor LLC | 338,222 | $1.17M | 0.03% | +63,165+23.0% | Added |
| Deerfield Management Company, L.P. (Series C) | 359,919 | $1.25M | 0.02% | +359,919 | New |
| Connor, Clark & Lunn Investment Management Ltd. | 437,051 | $1.51M | 0.01% | +437,051 | New |
| Two Sigma Investments, LP | 491,765 | $1.70M | 0.00% | −11,838−2.4% | Reduced |
| Two Sigma Advisers, LP | 590,900 | $2.04M | 0.00% | −95,600−13.9% | Reduced |
| Northern Trust Corp | 622,428 | $2.15M | 0.00% | +119,780+23.8% | Added |
| Arrowstreet Capital, Limited Partnership | 737,670 | $2.55M | 0.00% | +724,009+5,299.8% | Added |
| Aquilo Capital Management, LLC | 762,498 | $2.64M | 2.97% | 00.0% | Unchanged |
| Jacobs Levy Equity Management, Inc | 821,746 | $2.84M | 0.01% | −228,443−21.8% | Reduced |
| Bank of Montreal | 814,955 | $2.85M | 0.00% | +814,955 | New |
| Renaissance Technologies LLC | 828,097 | $2.87M | 0.00% | +108,600+15.1% | Added |
| Dimensional Fund Advisors LP | 980,318 | $3.39M | 0.00% | −104,963−9.7% | Reduced |
| Nuveen Asset Management, LLC | 1,199,623 | $4.15M | 0.00% | +294,180+32.5% | Added |
| Baillie Gifford & Co | 1,519,341 | $5.26M | 0.00% | −329,410−17.8% | Reduced |
| Acadian Asset Management LLC | 1,609,874 | $5.57M | 0.02% | +34,916+2.2% | Added |
| State Street Corp | 1,647,162 | $5.70M | 0.00% | +81,855+5.2% | Added |
| Parkman Healthcare Partners LLC | 1,716,132 | $5.94M | 0.76% | −76,608−4.3% | Reduced |
| Goldman Sachs Group Inc | 1,746,268 | $6.04M | 0.00% | +696,896+66.4% | Added |
| Eversept Partners, LP | 1,841,989 | $6.37M | 0.49% | +102,860+5.9% | Added |
| Geode Capital Management, LLC | 1,856,956 | $6.43M | 0.00% | +132,015+7.7% | Added |
| Millennium Management LLC | 2,031,745 | $7.03M | 0.01% | −2,330,148−53.4% | Reduced |
| Kynam Capital Management, LP | 2,066,447 | $7.15M | 0.55% | +42,764+2.1% | Added |
| Citadel Advisors LLC | 2,126,655 | $7.36M | 0.01% | +506,748+31.3% | Added |
| Samsara BioCapital, LLC | 2,196,814 | $7.60M | 1.46% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 2,250,132 | $7.79M | 0.01% | +250,132+12.5% | Added |
| MPM Oncology Impact Management LP | 2,832,064 | $9.80M | 1.47% | −211,282−6.9% | Reduced |
| Point72 Asset Management, L.P. | 2,997,453 | $10.4M | 0.04% | −1,450,181−32.6% | Reduced |
| Vanguard Group Inc | 4,195,072 | $14.5M | 0.00% | +639,732+18.0% | Added |
| BlackRock, Inc. | 7,016,119 | $24.3M | 0.00% | +7,016,119 | New |
| Suvretta Capital Management, LLC | 7,187,495 | $24.9M | 0.89% | −521,195−6.8% | Reduced |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −235,397−100.0% | Sold out |
| Tejara Capital Ltd | 0 | $0 | 0.00% | −203,145−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −97,888−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −60,761−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −50,718−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −43,426−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −31,311−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −16,463−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −12,829−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −11,725−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −10,853−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |
| Susquehanna Fundamental Investments, LLC | – | – | – | – | Not filed |